Methylene Blue for the Treatment of Radiation-Induced Oral Mucositis during Head and Neck Cancer Treatment: An Uncontrolled Cohort (2023)

Peer-Reviewed Study · Roldan CJ; Rosenthal D; Koyyalagunta L; Feng L; Warner K · August 7, 2023

Roldan CJ et al., 2023-08-07: Retrospective observational cohort at a US cancer centre of 85 patients with opioid-refractory oral mucositis pain during head and neck radiotherapy. Methylene blue oral rinse cut pain scores from 8 to 2 and oral function burden from 3.5 to 0, and allowed four of eleven patients with feeding tubes to resume oral intake.

Methylene blue oral rinse (MBOR) significantly decreased oral mucositis pain for at least 6.2 h (median + SD 8 ± 1.68 before vs. 2 ± 2.20 after; p < 0.0001)

Roldan CJ et al., 2023-08-07: Retrospective observational cohort at a US cancer centre of 85 patients with opioid-refractory oral mucositis pain during head and neck radiotherapy. Methylene blue oral rinse cut pain scores from 8 to 2 and oral function burden from 3.5 to 0, and allowed four of eleven patients with feeding tubes to resume oral intake. Study type: retrospective observational cohort, uncontrolled. N=85 identified, 58 analysed. Country: United States (MD Anderson Cancer Center). Dose/route: methylene blue oral rinse, concentration per full text; topical oral. Comparator: none (before/after within patient); 60% radiotherapy alone, 40% concurrent chemoradiotherapy. Results: pain 8 to 2 (p<0.0001) lasting at least 6.2 h; oral function burden 3.5 to 0; 4 of 11 with gastrostomy resumed oral alimentation; 2 required gastrostomy; adverse events 9 (15%). Funder/conflicts: per full text (same group as MTM-21, which declares a patent application on methylene blue for oral pain). Symptom control, not anti-tumour. Study type: uncontrolled series.